This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dawson, A. Articles by Struthers, A. D Search for Related Content PubMed PubMed Citation Articles by Dawson, A. Articles by Struthers, A. D Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?

Review: Vasopeptidase inhibitors in heart failure

Department of Clinical Pharmacology & Therapeutics, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY Scotland

Allan D Struthers

Department of Clinical Pharmacology & Therapeutics, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY Scotland, a.d.struthers@ dundee.ac.uk

Considerable attention has recently focused on the vasopeptidase inhibitors (VPI), a new class of drug that combines angiotensin-converting enzyme (ACE) inhibitor activity with inhibition of natriuretic peptide breakdown. In theory, a drug with these properties may be beneficial both in hypertension and in heart failure. Whilst the efficacy of VPIs in hypertension has been consistently demonstrated in pre-clinical and clinical studies, the role of VPIs, if any, in heart failure is less clear, since numerous small studies have produced conflicting results. Furthermore, preliminary results from the recently completed Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE) study have failed to establish the VPI, omapatrilat, as a first line therapy in the treatment of chronic heart failure. We review the literature on VPIs in heart failure and discuss possible reasons for the reported lack of benefit over ACE inhibitors.

Key Words: vasopeptidase inhibitors • heart failure • omapatrilat • natriuretic peptides

References

• Schrier RW, Abraham WT Hormones and hemodynamics in heart failure. N Engl J Med 1999;341(8):577-85.[Free Full Text]
• Kjær A., Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol 2001;21:661-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
• The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
• Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an ACE inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. NEnglJMed 2000;342:145-53.[Abstract/Free Full Text]
• Levin ER, Gardner DG, Samson WK Natriuretic peptides. N Engl J Med 1998;339:321-8.[Free Full Text]
• Kalra PR, Anker SD, Coats AJS Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51:495-509.[Free Full Text]
• Sagnella GA Atrial natriuretic peptide mimetics and vasopeptidase inhibitors. Cardiovasc Res 2001;51: 416-28.[Abstract/Free Full Text]
• Hughes S. OCTAVE: Omapatrilat in hypertension; 2.17% incidence of angioedema. Heartwire Mar 20, 2002. Available from: http://www.theheart.org
• Troughton RW, Rademaker MT, Powell JD et al. Beneficial renal and haemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension 2000;36:523-30.[Abstract/Free Full Text]
• Chen HH, Lainchbury JG, Matsuda Y., Harty GJ, Burnett JC Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 2001;38:187-91.[Abstract/Free Full Text]
• Lainchbury JG, Burnett JC The cardiac hormone atrial natriuretic peptide mediates haemodynamic actions of dual enzyme inhibition in early left ventricular dysfunction. Circulation 1999;100(suppl 1):I-438 Abstract.
• Holzgrefe HH,Arthur SR, Powell JR Effect of vasopeptidase inhibition with omapatrilat in a canine model of tachycardia-induced heart failure. J Am Coll Cardiol 2000:234A Abstract.
• Trippodo NC, Robl JA, Asaad MM et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-52.[Abstract/Free Full Text]
• Trippodo NC, Fox M., Monticello M., Panchal BC, Asaad MM Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition. Circulation 1998;98(suppl 17):Abstract.
• Klapholz M.,Thomas I., Eng C. et al. Effects of omapatrilat on hemodynamics and safety in patients with heart failure. Am J Cardiol 2001;88:657-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McClean DR, Ikram H., Garlick AH, Richars AM, Nicholls MG, Crozier IG The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000; 36:479-86.[Abstract/Free Full Text]
• McClean DR, Ikram H., Crozier IG, Reynolds M., Richards AM, Nicholls MG Omapatrilat improves volume homeostasis in chronic heart failure. J Am Coll Cardiol 2000;35(suppl A):232 Abstract.
• Udelson JE,Antonopoulos GV, Prouix G. et al. Comparison of long-term dual vasopeptidase inhibition with omapatrilat to ACE inhibition with lisinopril on ventricular volumes in patients with heart failure. Circulation 2000;102(suppl):II-536 Abstract.
• Young CM, Ikram H., McClean DR, Barmby D., Reynolds M. Long term hemodynamic effects of omapatrilat, a combined neutral endopeptidase and ACE inhibitor in chronic heart failure. NZ Med J 2001;114:242-3 Abstract.
• Ikram H., McClean DR, Mehta S. et al. Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure. J Am Coll Cardiol 1999:185A Abstract.
• McClean DR, Ikram H., Garlick AH, Crozier IG Effects of omapatrilat on systemic arterial function in patients with chronic heart failure. Am J Cardiol 2001:87:565-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mitchell GF, Block AJ, Hartley HL, Tardif JC, Rouleau JL, Pfeffer MA The vasopeptidase inhibitor, omapatrilat, has a favorable pressure-independent effect on conduit vessel stiffness in patients with congestive heart failure. Circulation 1999;100(suppl 1):I-646 Abstract.
• Kostis JB, Rouleau JL, Pfeffer MA et al. Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: evidence from the omapatrilat heart failure program. J Am Coll Cardiol 2000;35:240A Abstract.
• Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 2000;356:615-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Packer M., Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6.[Abstract/Free Full Text]
• Nathisuwan S., Talbert RL A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy 2002;22:27-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 3, 156-159 (2002)
DOI: 10.3317/jraas.2002.035


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dawson, A. Articles by Struthers, A. D Search for Related Content PubMed PubMed Citation Articles by Dawson, A. Articles by Struthers, A. D Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?